AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02561754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet (eSLD)
Description: eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
Study NCT02561754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet (CD)
Description: CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
Study NCT02561754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional Diet (CD)
Description: CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
Study NCT02561754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face (FTF)
Description: FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
Study NCT02561754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology (TECH)
Description: TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
Study NCT02561754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad with FaceTime
Description: TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
Study NCT00408239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral
Study NCT00408239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: Sub cutaneous
Study NCT03507465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Plus Low-Dose Metronomic Capecitabine
Description: Letrozole Plus Low-Dose Metronomic Capecitabine
Study NCT03507465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-T
Description: Epirubicin/Cyclophosphamide Followed by Docetaxel
Study NCT03834051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation Rectal Administration Open Label
Study NCT04717037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olive Oil Massage
Description: olive oil massage application.
Study NCT03777982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
Study NCT00821574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin: daily 80 mg, oral
Study NCT00821574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan: daily 160 mg, oral
Study NCT00821574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide: daily 12.5mg, oral
Study NCT03777982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
Study NCT03777982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
Study NCT03777982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist or Antagonist
Description: Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
Study NCT03737929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Description: In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
Study NCT03737929 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous catheter ablation
Description: In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
Study NCT06054490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses self-management techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state. In addition, relaxation techniques, sleep hygiene, diet modification, thermotherapy, encouragement to practice social and aerobic activities, and how to prevent risk factors and bad habits.
Study NCT06054490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
Study NCT06054490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercises
Description: It is based on home self-exercise routine. Basic exercise therapy includes mobilization, stretching, and muscle strengthening exercises
Study NCT02011906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 3
Study NCT02011906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin E
Study NCT02011906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo of omega 3
Study NCT02011906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo of vitamin E
Study NCT02011906 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo of vitamin E
Study NCT03841396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: All participants received a single dose of sodium chloride as placebo
Study NCT01498068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
Study NCT01498068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alfa-2a
Description: Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
Study NCT01498068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is >= 75kg) per day for 24 or 48 weeks.
Study NCT03431259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Gateway
Description: Patients will be enrolled in the Patient Gateway app.
Study NCT01463501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Description: Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
Study NCT01463501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
Study NCT04125927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptamine
Description: Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
Study NCT00940771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boosted Atazanavir
Description: Boosted Atazanavir, once a day dose adjusted for child's weight for 6 months.
Study NCT04965701 — intervention group
Intervention type: DRUG
Intervention: Osimertinib 80 MG
Description: Osimertinib is administered according to clinical practice at the recommended dose of 80 mg, orally, once a day.
Study NCT00802308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulphate
Description: Extended release tablet combined with alcohol or water
Study NCT00802308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine sulphate
Description: Extended release tablet combined with alcohol or water
Study NCT03011099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton training
Description: During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
Study NCT03011099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
Study NCT04004234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manganese Chloride
Description: Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
Study NCT04004234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
Study NCT04004234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
Study NCT04004234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
Study NCT00125255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Description: S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
Study NCT00125255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Peel
Description: Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
Study NCT00129246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
Study NCT00129246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
Study NCT00129246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
Study NCT00568022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m\^2, once every 3 weeks, up to 6 cycles
Study NCT00568022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: Tablets, Oral, 1650(2000)mg/m\^2, twice daily for 2 weeks, one week off, up to 6 cycles
Study NCT02246790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biatrial radiofrequency ablation and CABG
Description: Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
Study NCT02246790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial radiofrequency ablation and CABG
Description: Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
Study NCT04409925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhDNase I
Description: Inhaled nebulisations
Study NCT01670344 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment with investigational method (virtual implant positioning system)
Study NCT01670344 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Treatment with surgical standard of care
Study NCT04084236 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation
Study NCT04084236 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: no stimulation
Study NCT03942796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lyrica, vronogabic (pregabalin)
Description: Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
Study NCT03942796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100
Description: Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
Study NCT05153616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Full night attended polysomnography to diagnose periodic limb movements
Study NCT04906564 — intervention group
Intervention type: OTHER
Intervention: Identification of genetic variants
Description: Identification of genetic variants
Study NCT02786017 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Conventional therapy
Description: Patients will receive the conventional therapy.
Study NCT02786017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injectable Collagen Scaffold + HUC-MSCs
Description: Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5\*10\^8.
Study NCT02589938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Hygiene
Description: Oral hygiene care provided per individual institutions standard of care.
Study NCT02589938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Oral Hygiene + True Acupuncture
Description: Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
Study NCT02589938 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Oral Hygiene + Sham Acupuncture
Description: Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
Study NCT02680249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-656
Study NCT02158442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Isolated Limb Perfusion (PILP) delivery
Description: The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
Study NCT02158442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timentin
Description: The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
Study NCT02158442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timentin
Description: The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
Study NCT04488614 — intervention group
Intervention type: PROCEDURE
Intervention: Breast Concervative or Meastectomy
Description: National treatment guidelines in Norway
Study NCT03129568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDC infusion
Description: Injection of CDCs (0.3 million per kg of body weight).
Study NCT00613873 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy and Questionnaire
Description: Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: Abolishes pituitary sensitivity to GnRH.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: Abolishes pituitary sensitivity to GnRH.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin-GnRH
Description: GnRH is used to stimulate the pituitary gland to produce LH and FSH.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadorelin-GnRH
Description: GnRH is used to stimulate the pituitary gland to produce LH and FSH.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant LH
Description: Used to stimulate ovarian function in women.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant LH
Description: Used to stimulate ovarian function in women.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: An aromatase inhibitor.
Study NCT01457703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: An aromatase inhibitor.
Study NCT00622050 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No TV viewing reduction
Description: In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
Study NCT00622050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV viewing reduction
Description: In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
Study NCT00828594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT00828594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, sorafenib
Study NCT05716802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dance/movement therapy
Description: dance/movement therapy plus treat as usual
Study NCT05716802 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual
Description: The patients received regular daily antipsychotic medication and supportive psychotherapy once a week. They also participated in daily activities from Monday to Friday for at least two hours each day, including indoor activities (watching TV, playing games, playing poker) and outside activities (walking and doing radio gymnastics).